Comparative Pharmacology
Head-to-head clinical analysis: HUMALOG versus HUMALOG MIX 50 50 KWIKPEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HUMALOG versus HUMALOG MIX 50 50 KWIKPEN.
HUMALOG vs HUMALOG MIX 50/50 KWIKPEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin lispro is a rapid-acting insulin analog that lowers blood glucose by binding to insulin receptors on skeletal muscle and adipocytes, leading to increased glucose uptake and reduced hepatic glucose production.
Insulin lispro is a rapid-acting insulin analog that lowers blood glucose by stimulating peripheral glucose uptake, especially in skeletal muscle and adipose tissue, and by inhibiting hepatic glucose production. It binds to the insulin receptor, activating tyrosine kinase signaling.
Subcutaneous injection: 0.2-1.0 units/kg/day divided into 3 or more doses, given within 15 minutes before or immediately after a meal. Typical total daily dose range 0.5-1.0 units/kg/day.
Subcutaneous injection: individualized dose based on metabolic needs, blood glucose monitoring, and prior insulin therapy. Typically administered within 15 minutes before meals or immediately after meals. Total daily dose: 0.5-1.0 units/kg/day in divided doses. For the mix 50/50, half as basal (intermediate-acting component) and half as bolus (rapid-acting component).
None Documented
None Documented
Subcutaneous: 0.5-1.0 hour (insulin lispro); longer with renal impairment (up to 1.5-3 hours).
0.5-1 hour (insulin lispro); terminal half-life is approximately 1 hour. Clinically, the rapid clearance allows for flexible dosing timing relative to meals.
Renal: 60-80% as unchanged drug; biliary/fecal: minor (<10%).
Renal: 60-80% as metabolites; hepatic metabolism accounts for most of the remainder. Fecal excretion is minimal.
Category C
Category C
Insulin
Insulin